Back to Journals » Infection and Drug Resistance » Volume 5

Ceftaroline in complicated skin and skin-structure infections

Authors Hernandez, Lema S, Tyring, Mendoza N

Received 24 November 2011

Accepted for publication 12 December 2011

Published 19 January 2012 Volume 2012:5 Pages 23—35

DOI https://doi.org/10.2147/IDR.S17432

Review by Single anonymous peer review

Peer reviewer comments 3



Paul O Hernandez1, Sergio Lema2, Stephen K Tyring3, Natalia Mendoza2,4
1University of Texas School of Medicine at San Antonio, San Antonio, TX, 2Woodhull Medical and Mental Health Center, Brooklyn, NY, 3Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX, USA; 4Department of Dermatology, El Bosque University, Bogotá, Colombia

Abstract: Ceftaroline is an advanced-generation cephalosporin antibiotic recently approved by the US Food and Drug Administration for the treatment of complicated skin and skin-structure infections (cSSSIs). This intravenous broad-spectrum antibiotic exerts potent bactericidal activity by inhibiting bacterial cell wall synthesis. A high affinity for the penicillin-binding protein 2a (PBP2a) of methicillin-resistant Staphylococcus aureus (MRSA) makes the drug especially beneficial to patients with MRSA cSSSIs. Ceftaroline has proved in multiple well-conducted clinical trials to have an excellent safety and efficacy profile. In adjusted doses it is also recommended for patients with renal or hepatic impairment. Furthermore, the clinical effectiveness and high cure rate demonstrated by ceftaroline in cSSSIs, including those caused by MRSA and other multidrug-resistant strains, warrants its consideration as a first-line treatment option for cSSSIs. This article reviews ceftaroline and its pharmacology, efficacy, and safety data to further elucidate its role in the treatment of cSSSIs.

Keywords: ceftaroline, cephalosporin, complicated skin and skin-structure infections, cSSSIs, MRSA, Teflaro®

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.